Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Classification results from multilevel PLS-DA and PLS-DA

From: Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

     Class. model No. of LVs Variance
X/Y
(%)
Sensitivity/
Specificity (%)
Class. accuracy
(%)
Permutation
p-value
Paired data All samples Control vs Treatment (n = 65p) Multilevel PLS-DA 2 58.9/50.9 87.9/87.9 87.9 < 0.001
  Partial response Control vs Treatment (n = 37p) Multilevel PLS-DA 2 55.7/61.7 80.0/80.0 80.0 < 0.001
  Stable disease Control vs Treatment (n = 28p) Multilevel PLS-DA 2 63.2/61.3 88.7/88.7 88.7 < 0.001
  Survivors Control vs Treatment (n = 44p) Multilevel PLS-DA 2 60.0/50.5 83.0/83.0 83.0 < 0.001
  Non-survivors Control vs Treatment (n = 19p) Multilevel PLS-DA 2 70.6/63.9 82.5/82.5 82.5 0.006
Unpaired data All samples Pre- vs
Post-treatment
(n = 65p) PLD-DA 2 50.3/29.2 80.7/57.1 68.9 < 0.001
  Pre-treatment Partial response vs
Stable disease
(n = 48)
(n = 32)
PLS-DA 2 51.5/19.3 56.7/60.2 58.4 0.231
  Post-treatment Partial response vs
Stable disease
(n = 41)
(n = 29)
PLS-DA NaN - - - -
  Pre-treatment Survivors vs
Non-survivors
(n = 57)
(n = 20)
PLS-DA NaN - - - -
  Post-treatment Survivors vs
Non-survivors
(n = 47)
(n = 21)
PLS-DA 3 62.8/32.1 58.4/75.3 70.1 0.009
  Post-treatment Epirubicin vs
Paclitaxel
(n = 29)
(n = 23)
PLS-DA 2 45.7/26.8 45.0/48.3 46.5 0.245
  1. The sensitivity is for detecting a treatment/stable disease/non-survivor/Paclitaxel spectrum; Variance X/Y, amount of variance from X/Y explained by the model; NaN, no valid model; p, pairs